Cargando…
Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and short survival. Today, the use of new polytherapeutic regimens increases clinical outcome of these patients opening new clinical scenario. A crucial issue related to the actual improvement achieved with these n...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569435/ https://www.ncbi.nlm.nih.gov/pubmed/33102398 http://dx.doi.org/10.1155/2020/8679751 |
_version_ | 1783596731026374656 |
---|---|
author | Argentiero, Antonella Calabrese, Angela Sciacovelli, Angela Monica Delcuratolo, Sabina Solimando, Antonio Giovanni Brunetti, Oronzo |
author_facet | Argentiero, Antonella Calabrese, Angela Sciacovelli, Angela Monica Delcuratolo, Sabina Solimando, Antonio Giovanni Brunetti, Oronzo |
author_sort | Argentiero, Antonella |
collection | PubMed |
description | Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and short survival. Today, the use of new polytherapeutic regimens increases clinical outcome of these patients opening new clinical scenario. A crucial issue related to the actual improvement achieved with these new regimens is represented by the occasional possibility to observe a radiological complete response of metastatic lesions in patients with synchronous primary tumor. What could be the best therapeutic management of these patients? Could surgery represent an indication? Herein, we reported a case of a patient with PDAC of the head with multiple liver metastases, who underwent first-line chemotherapy with mFOLFIRINOX. After 10 cycles, he achieved a complete radiological response of liver metastases and a partial response of pancreatic lesion. A duodenocephalopancreasectomy was performed. Due to liver a lung metastases after 8 months from surgery, a second-line therapy was started with a disease-free survival and overall survival of 8 months and 45 months, respectively. Improvement in the molecular characterization of PDAC could help in the selection of patients suitable for multimodal treatments. This trial is registered with NCT02892305 and NCT00855634. |
format | Online Article Text |
id | pubmed-7569435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-75694352020-10-22 Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option Argentiero, Antonella Calabrese, Angela Sciacovelli, Angela Monica Delcuratolo, Sabina Solimando, Antonio Giovanni Brunetti, Oronzo Can J Gastroenterol Hepatol Research Article Metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and short survival. Today, the use of new polytherapeutic regimens increases clinical outcome of these patients opening new clinical scenario. A crucial issue related to the actual improvement achieved with these new regimens is represented by the occasional possibility to observe a radiological complete response of metastatic lesions in patients with synchronous primary tumor. What could be the best therapeutic management of these patients? Could surgery represent an indication? Herein, we reported a case of a patient with PDAC of the head with multiple liver metastases, who underwent first-line chemotherapy with mFOLFIRINOX. After 10 cycles, he achieved a complete radiological response of liver metastases and a partial response of pancreatic lesion. A duodenocephalopancreasectomy was performed. Due to liver a lung metastases after 8 months from surgery, a second-line therapy was started with a disease-free survival and overall survival of 8 months and 45 months, respectively. Improvement in the molecular characterization of PDAC could help in the selection of patients suitable for multimodal treatments. This trial is registered with NCT02892305 and NCT00855634. Hindawi 2020-10-09 /pmc/articles/PMC7569435/ /pubmed/33102398 http://dx.doi.org/10.1155/2020/8679751 Text en Copyright © 2020 Antonella Argentiero et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Argentiero, Antonella Calabrese, Angela Sciacovelli, Angela Monica Delcuratolo, Sabina Solimando, Antonio Giovanni Brunetti, Oronzo Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option |
title | Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option |
title_full | Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option |
title_fullStr | Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option |
title_full_unstemmed | Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option |
title_short | Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option |
title_sort | complete response of synchronous liver metastasis in a pancreatic ductal adenocarcinoma, when surgery could represent a therapeutic option |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569435/ https://www.ncbi.nlm.nih.gov/pubmed/33102398 http://dx.doi.org/10.1155/2020/8679751 |
work_keys_str_mv | AT argentieroantonella completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption AT calabreseangela completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption AT sciacovelliangelamonica completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption AT delcuratolosabina completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption AT solimandoantoniogiovanni completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption AT brunettioronzo completeresponseofsynchronouslivermetastasisinapancreaticductaladenocarcinomawhensurgerycouldrepresentatherapeuticoption |